# Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell

> **NCT06441344** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Taizhou Hospital** · enrollment: 136 (estimated)

## Conditions studied

- SCLC
- Maintenance Treatment

## Interventions

- **DRUG:** Toripalimab plus Anlotinib
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT06441344
- **Lead sponsor:** Taizhou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-05-01
- **Final completion:** 2030-05-01
- **Target enrollment:** 136 (ESTIMATED)
- **Last updated:** 2024-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06441344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06441344, "Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small Cell". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06441344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*